124.15

21.04% -33.09

Pre-market: 125.50 1.35 +1.09%

Palvella Therapeutics Inc (PVLA)

Overview News Price History Discussions Forecast

Palvella Therapeutics Inc stock is traded at $124.15, with a volume of 558.09K. It is down -21.04% in the last 24 hours and up +9.77% over the past month. Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company whose vision is to become the rare disease biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases and vascular malformations for which there are no FDA-approved therapies. Its product candidate, QTORIN 3.9% rapamycin anhydrous gel, is currently in clinical development for microcystic lymphatic malformations and cutaneous venous malformations. It operates in single segment.

Previous Close:

$157.24

Open:

$155.72

24h Volume:

558.09K

Relative Volume:

2.12

Market Cap:

$1.78B

Revenue:

$1.30M

Net Income/Loss:

$-49.30M

P/E Ratio:

-29.78

EPS:

-4.1688

Net Cash Flow:

$-29.10M

1W Performance:

-14.98%

1M Performance:

+9.77%

6M Performance:

+26.67%

1Y Performance:

+320.70%

1-Day Range:

$123.97

$157.55

1-Week Range:

$123.97

$158.08

52-Week Range:

$29.59

$161.38

Palvella Therapeutics Inc Stock (PVLA) Company Profile

Name

Palvella Therapeutics Inc

Sector

Healthcare (1089)

Industry

Biotechnology (603)

Phone

(484) 253-1461

Address

353 W. LANCASTER AVENUE, WAYNE

Employee

Twitter

Next Earnings Date

2026-08-13

Latest SEC Filings

PVLA's Discussions on Twitter

Compare PVLA vs VRTX, REGN, ARGX, RVMD, ALNY

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
PVLA Palvella Therapeutics Inc	124.15	1.78B	1.30M	-49.30M	-29.10M	-4.1688
VRTX Vertex Pharmaceuticals Inc	480.50	121.95B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	672.15	70.47B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	846.19	52.94B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	180.39	38.35B	742.00K	-1.37B	-1.07B	-7.0731
ALNY Alnylam Pharmaceuticals Inc	272.67	36.40B	4.29B	577.22M	641.34M	4.2086

Palvella Therapeutics Inc Stock (PVLA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-07-26	Initiated	Mizuho	Outperform
Dec-05-25	Initiated	BTIG Research	Buy
Dec-04-25	Initiated	Craig Hallum	Buy
Nov-19-25	Upgrade	Raymond James	Outperform → Strong Buy
Sep-09-25	Initiated	Oppenheimer	Outperform
Aug-06-25	Initiated	Raymond James	Outperform
Jul-21-25	Initiated	Truist	Buy
Apr-09-25	Initiated	Chardan Capital Markets	Buy
Mar-26-25	Initiated	Stifel	Buy
Mar-07-25	Initiated	Scotiabank	Sector Outperform
Feb-20-25	Initiated	Canaccord Genuity	Buy
Feb-05-25	Initiated	TD Cowen	Buy
Dec-26-24	Initiated	H.C. Wainwright	Buy
Dec-18-24	Initiated	Cantor Fitzgerald	Overweight
Mar-13-20	Upgrade	Robert W. Baird	Neutral → Outperform
Jul-30-19	Downgrade	Robert W. Baird	Outperform → Neutral
May-14-19	Initiated	Robert W. Baird	Outperform
Mar-19-18	Initiated	Evercore ISI	Outperform
Mar-19-18	Initiated	Jefferies	Buy
Jan-16-18	Reiterated	H.C. Wainwright	Buy
May-30-17	Initiated	Rodman & Renshaw	Buy
Aug-05-16	Resumed	ROTH Capital	Buy
Aug-12-15	Initiated	JMP Securities	Mkt Outperform
Jul-27-15	Initiated	Oppenheimer	Outperform
Jul-22-15	Initiated	ROTH Capital	Buy

View All

Palvella Therapeutics Inc Stock (PVLA) Latest News

Jul 20, 2026

Palvella Therapeutics (PVLA) Sees Significant Decline - GuruFocus

Jul 20, 2026

Jul 17, 2026

Palvella Therapeutics (PVLA) COO exercises options, then sells 4,302 shares - Stock Titan

Jul 17, 2026

Palvella Therapeutics (PVLA) Submits Initial Module of NDA For QTORIN - Yahoo Finance

Jul 15, 2026

Jul 14, 2026

Palvella Therapeutics posts corporate presentation highlighting Phase 3 SELVA wins, NDA rolling review and $262M cash - TradingView

Jul 14, 2026

Jul 11, 2026

Palvella Therapeutics (PVLA) Proxy filing Summary - Quartr

Jul 11, 2026

Jul 10, 2026

Palvella Therapeutics (PVLA) Faces Pullback After Recent Gains – Key Support Levels in FocusRevenue Growth Stocks - dars.gov.et

Jul 10, 2026

Jul 08, 2026